DSM Capital Partners LLC Takes Position in Edwards Lifesciences Co. (NYSE:EW)

DSM Capital Partners LLC purchased a new position in Edwards Lifesciences Co. (NYSE:EWFree Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 371 shares of the medical research company’s stock, valued at approximately $28,000.

A number of other hedge funds have also bought and sold shares of the company. Hsbc Holdings PLC increased its stake in Edwards Lifesciences by 32.1% during the fourth quarter. Hsbc Holdings PLC now owns 1,616,969 shares of the medical research company’s stock valued at $123,346,000 after purchasing an additional 393,297 shares during the last quarter. Intech Investment Management LLC raised its stake in Edwards Lifesciences by 65.8% during the fourth quarter. Intech Investment Management LLC now owns 16,450 shares of the medical research company’s stock worth $1,254,000 after acquiring an additional 6,526 shares during the period. Johnson Financial Group Inc. lifted its holdings in Edwards Lifesciences by 23.0% in the fourth quarter. Johnson Financial Group Inc. now owns 771 shares of the medical research company’s stock worth $59,000 after acquiring an additional 144 shares during the last quarter. Nixon Peabody Trust Co. acquired a new position in Edwards Lifesciences in the fourth quarter valued at approximately $643,000. Finally, Skopos Labs Inc. bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $312,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Edwards Lifesciences

In other news, Director Michael A. Mussallem sold 29,350 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the completion of the sale, the director now directly owns 4,486 shares of the company’s stock, valued at $388,801.62. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Edwards Lifesciences news, CEO Bernard J. Zovighian bought 580 shares of the company’s stock in a transaction dated Monday, May 6th. The shares were bought at an average price of $85.74 per share, for a total transaction of $49,729.20. Following the acquisition, the chief executive officer now directly owns 3,268 shares of the company’s stock, valued at $280,198.32. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael A. Mussallem sold 29,350 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the completion of the sale, the director now directly owns 4,486 shares of the company’s stock, valued at $388,801.62. The disclosure for this sale can be found here. Insiders sold a total of 180,707 shares of company stock valued at $16,034,814 in the last three months. 1.27% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Price Performance

NYSE EW traded up $0.52 on Monday, reaching $87.98. The company’s stock had a trading volume of 1,786,600 shares, compared to its average volume of 3,551,060. The firm’s 50 day moving average is $89.68 and its two-hundred day moving average is $81.74. The stock has a market cap of $53.02 billion, a PE ratio of 37.92, a PEG ratio of 3.22 and a beta of 1.10. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EWGet Free Report) last released its earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.64 by $0.02. The business had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on EW shares. Stifel Nicolaus boosted their price objective on Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a research report on Friday, April 26th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. Royal Bank of Canada lifted their price objective on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Finally, Wells Fargo & Company lifted their price target on Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a report on Friday, April 26th. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $94.31.

View Our Latest Report on Edwards Lifesciences

Edwards Lifesciences Company Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Read More

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWFree Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.